Advice
following a full submission
apremilast (Otezla®) is accepted for use within NHS Scotland.
Indication under review: for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA).
In two phase III, randomised, placebo-controlled studies in patients with moderate to severe plaque psoriasis, a significantly greater proportion of patients who received apremilast achieved at least 75% improvement in the Psoriasis Area and Severity Index (PASI) score at 16 weeks compared with those who received placebo.
Download detailed advice251KB (PDF)
Medicine details
- Medicine name:
- apremilast (Otezla) plaque psoriasis
- SMC ID:
- 1052/15
- Indication:
- for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or pSoralen and ultraviolet A light (PUVA).
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Musculoskeletal and joint diseases, Skin
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 June 2015